"With this approval, Effient will be directly competing with blockbuster drug, Plavix made by Sanofi-Aventis (WKN: 920657) and Bristol-Myers Squibb (WKN: 850501)."
newsroom.lilly.com/releasedetail.cfm?ReleaseID=395752
Interessant auch folgende Aussage von John Jenkins, seines Zeichens "director of New Drugs at the FDA Center for Drug Evaluation and Research": "Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug."
www.tradingmarkets.com/.site/news/TOP%20STORY/2415700/
Das sind ungewöhnliche, recht marktliberale Töne von der FDA, siehe dazu auch:
www.forbes.com/2009/07/08/...-contributors-biologic-drugs.html
newsroom.lilly.com/releasedetail.cfm?ReleaseID=395752
Interessant auch folgende Aussage von John Jenkins, seines Zeichens "director of New Drugs at the FDA Center for Drug Evaluation and Research": "Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug."
www.tradingmarkets.com/.site/news/TOP%20STORY/2415700/
Das sind ungewöhnliche, recht marktliberale Töne von der FDA, siehe dazu auch:
www.forbes.com/2009/07/08/...-contributors-biologic-drugs.html
